![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Hematol.
Sec. Blood Cancer
Volume 3 - 2024 | doi: 10.3389/frhem.2024.1483322
This article is part of the Research Topic Myeloproliferative Neoplasms: Updates for Patients and Healthcare Providers View all 4 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Thank you and the thoughtful reviewers for the insightful critiques, positive comments, and constructive suggestions regarding our manuscript entitled, "Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adults". We appreciate the critique and fully addressed each issue raised, which improved our manuscript. We summarize our overall response below and provide a more detailed response to each Reviewer.This review paper refers to younger patients with MPNs who have been one of the centers of interest in MPN in the last year. The paper contains useful informations, but a minor correction is advised, which should follow mentioned comments in the following sections:1. Introduction: the percentage of transformation into AL is not the same for all MPNs, please correct. Thank you for noting this important point -we added 5 references (listed below) and cite our prior references 6 and 11 for these percentages. The text was clarified to include % transformation rates based on initial diagnosis.
Keywords: MPN, Myeloproliferative neoplasm, Children, Adolescents and young adults, Therapy -
Received: 19 Aug 2024; Accepted: 05 Nov 2024.
Copyright: © 2024 Resar and Jain. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Linda Resar, School of Medicine, Johns Hopkins University, Baltimore, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.